eBulletin Newsletter

NCCN Flash Updates: NCCN Guidelines and NCCN Templates Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and the NCCN Drugs and Biologics Compendium (NCCN Compendium^®) for Thyroid Carcinoma. These NCCN Guidelines^® are currently available as Version 3.2021.

Link directly to the Updates section of the NCCN Guidelines: 
Thyroid Carcinoma

Updates in Version 3.2021

• Treatment of locally recurrent, advanced, and/or metastatic differentiated thyroid carcinoma not amenable to RAI therapy (including bone and CNS metastases) (PAP-9, PAP-10, FOLL-8, FOLL-9, HURT-8, HURT-9)
  • Under Consider systemic therapy, added: Cabozantinib if progression after lenvatinib and/or sorafenib. This is a category 1 recommendation for papillary carcinoma and a category 2A option for follicular carcinoma and Hürthle cell carcinoma.
  • Modified footnote: Commercially available small molecule kinase inhibitors (such as axitinib, everolimus, pazopanib, sunitinib, vandetanib, vemurafenib [BRAF positive], or dabrafenib [BRAF positive], or cabozantinib [all are category 2A]) can be considered if clinical trials are not available or appropriate.

Previous updates to the NCCN Guidelines for Thyroid Carcinoma can be found in the UPDATES section of the current version




NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer to reflect the currently published NCCN Guidelines for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer v3.2021.

• Changes to the Indication section have been made to the following templates:
  • OVA2: IV PACLitaxel/Intraperitoneal CISplatin/Intraperitoneal PACLitaxel
  • OVA7: CARBOplatin
  • OVA11: PACLitaxel Weekly/CARBOplatin Weekly
  • OVA23: Olaparib
  • OVA29: Pembrolizumab
  • OVA37: Leuprolide acetate
  • OVA61: Rucaparib
  • OVA63: Anastrozole
  • OVA64: Niraparib
  • OVA74: Olaparib + Bevacizumab
  • OVMUC1: Fluorouracil/Leucovorin/OXALIplatin
  • OVMUC2: Fluorouracil/Leucovorin/OXALIplatin + Bevacizumab
  • OVMUC3: CapeOX (Capecitabine/OXALIplatin)
  • OVMUC4: CapeOX (Capecitabine/OXALIplatin) + Bevacizumab
  • OVSCST9: CISplatin/Etoposide
• References have been updated on the following templates:
  • OVA23: Olaparib
  • OVA61: Rucaparib
• Emetic Risk section has been updated on the following templates:
  • OVA11: PACLitaxel Weekly/CARBOplatin Weekly
  • OVCARS3: PACLitaxel/Ifosfamide
  • OVMUC1: Fluorouracil/Leucovorin/OXALIplatin
  • OVMUC2: Fluorouracil/Leucovorin/OXALIplatin + Bevacizumab
  • OVMUC4: CapeOX (Capecitabine/OXALIplatin) + Bevacizumab
• Changes to the Premedication section have been made to the following template:
  • OVA57: DOCEtaxel/CARBOplatin Weekly
• Changes to the Chemotherapy Regimen section have been made to the following templates:
  • OVA4: PACLitaxel/CARBOplatin Every 21 Days
  • OVA8:  CISplatin
  • OVA9:  Cyclophosphamide
  • OVA14: Irinotecan
  • OVA29: Pembrolizumab
  • OVA37: Leuprolide acetate
  • OVA58: PACLitaxel/CARBOplatin/Bevacizumab + Maintenance Bevacizumab (ICON-7)
  • OVA59: PACLitaxel/CARBOplatin/Bevacizumab + Maintenance Bevacizumab (GOG-218)
  • OVA64: Niraparib
  • OVA67: CISplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
  • OVA74: Olaparib + Bevacizumab
  • OVMUC1: Fluorouracil/Leucovorin/OXALIplatin
  • OVSCST6: PACLitaxel/Ifosfamide
  • OVSCST7: VAC (VinCRIStine/DACTINomycin/Cyclophosphamide)
  • OVSCST8: Leuprolide acetate
  • OVMGCT11: VAC (VinCRIStine/DACTINomycin/Cyclophosphamide)
• Drug information notes for the following agents have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
  • DACTINomycin
  • DOXOrubicin
  • Ifosfamide
  • Leuprolide acetate
  • Melphalan
  • PACLitaxel- applies to template OVSCST6 only route and associated notes in SPSI
  • Pembrolizumab
  • VinBLAStine
  • vinCRIStine
  • VinORELBine

NCCN has published updates to the NCCN Templates^® for Gastric Cancer to reflect the currently published NCCN Guidelines for Gastric Cancer v5.2021.

• The following NEW NCCN Templates have been published:
  • GAS107: Dostarlimab-gxly

NCCN has published updates to the NCCN Templates for Hepatobiliary Cancer to reflect the currently published NCCN Guidelines for Hepatobiliary Cancer v5.2021.

• The following NEW NCCN Templates have been published:
  • HEP43: Dostarlimab-gxly

NCCN has updated the NCCN Radiation Therapy Compendium™ to reflect recommendations within the following NCCN Guidelines:

• Small Cell Lung Cancer, Version 1.2022

NCCN has published updates to the following NCCN Guidelines with NCCN Evidence Blocks™:

• Prostate Cancer, Version 1.2022 
• Multiple Myeloma, Version 1.2022
• Systemic Light Chain Amyloidosis, Version 1.2022
• Waldenström’s Macroglobulinemia, Version 1.2022
• Non-Small Cell Lung Cancer, Version 6.2021
• Gastric Cancer, Version 5.2021

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Please  note:  1. Third Party Content. The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content FTP site: ftp://ftp1.nccn.org (To access: user name:content; password is NCCNcontent) (“Third Party Content”). Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works.

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.